Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension

Yukihiro Saito, Kazufumi Nakamura, Katsumasa Miyaji, Satoshi Akagi, Hiroki Mizoguchi, Aiko Ogawa, Soichiro Fuke, Hideki Fujio, Takahiko Kiyooka, Satoshi Nagase, Kunihisa Kohno, Hiroshi Morita, Kengo F. Kusano, Hiromi Matsubara, Tohru Ohe, Hiroshi Itoh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Acute vasoreactivity testing for patients with pulmonary arterial hypertension (PAH) has been reported to be useful to identify patients with sustained beneficial response to oral calcium-channel blockers (CCBs), but there is a risk of exacerbation during the testing with oral CCBs. Therefore, we developed a testing method utilizing intravenous nicardipine, a short-acting CCB, and examined the safety and usefulness of acute vasoreactivity testing with nicardipine in PAH patients. Acute vasoreactivity testing with nicardipine was performed in 65 PAH patients. Nicardipine was administered by short-time continuous infusion (1 μg·kg-1·min-1 for 5 min and 2 μg·kg-1·min-1 for 5 min) followed by bolus injection (5 μg/kg). Hemodynamic responses were continuously measured using a right heart catheter. Acute responders were defined as patients who showed a decrease in mean pulmonary artery pressure of at least 10 mmHg to an absolute level below 40 mmHg with preserved or increased cardiac output. Two acute responders and sixty-three non-acute responders were identified. There was no hemodynamic instability requiring additional inotropic agents or death during the testing. Acute responders had good responses to long-term oral CCBs. The acute vasoreactivity testing with nicardipine might be safe and useful for identifying CCB responders in PAH patients.

Original languageEnglish
Pages (from-to)206-212
Number of pages7
JournalJournal of Pharmacological Sciences
Volume120
Issue number3
DOIs
Publication statusPublished - 2012

Fingerprint

Nicardipine
Pulmonary Hypertension
Calcium Channel Blockers
Hemodynamics
Cardiac Catheters
Cardiac Output
Pulmonary Artery
Safety
Pressure
Injections

Keywords

  • Acute vasoreactivity testing
  • Calcium-channel blocker
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension. / Saito, Yukihiro; Nakamura, Kazufumi; Miyaji, Katsumasa; Akagi, Satoshi; Mizoguchi, Hiroki; Ogawa, Aiko; Fuke, Soichiro; Fujio, Hideki; Kiyooka, Takahiko; Nagase, Satoshi; Kohno, Kunihisa; Morita, Hiroshi; Kusano, Kengo F.; Matsubara, Hiromi; Ohe, Tohru; Itoh, Hiroshi.

In: Journal of Pharmacological Sciences, Vol. 120, No. 3, 2012, p. 206-212.

Research output: Contribution to journalArticle

Saito, Y, Nakamura, K, Miyaji, K, Akagi, S, Mizoguchi, H, Ogawa, A, Fuke, S, Fujio, H, Kiyooka, T, Nagase, S, Kohno, K, Morita, H, Kusano, KF, Matsubara, H, Ohe, T & Itoh, H 2012, 'Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension', Journal of Pharmacological Sciences, vol. 120, no. 3, pp. 206-212. https://doi.org/10.1254/jphs.12114FP
Saito, Yukihiro ; Nakamura, Kazufumi ; Miyaji, Katsumasa ; Akagi, Satoshi ; Mizoguchi, Hiroki ; Ogawa, Aiko ; Fuke, Soichiro ; Fujio, Hideki ; Kiyooka, Takahiko ; Nagase, Satoshi ; Kohno, Kunihisa ; Morita, Hiroshi ; Kusano, Kengo F. ; Matsubara, Hiromi ; Ohe, Tohru ; Itoh, Hiroshi. / Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension. In: Journal of Pharmacological Sciences. 2012 ; Vol. 120, No. 3. pp. 206-212.
@article{a4e8ddbf80874d3780e6825cdc868342,
title = "Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension",
abstract = "Acute vasoreactivity testing for patients with pulmonary arterial hypertension (PAH) has been reported to be useful to identify patients with sustained beneficial response to oral calcium-channel blockers (CCBs), but there is a risk of exacerbation during the testing with oral CCBs. Therefore, we developed a testing method utilizing intravenous nicardipine, a short-acting CCB, and examined the safety and usefulness of acute vasoreactivity testing with nicardipine in PAH patients. Acute vasoreactivity testing with nicardipine was performed in 65 PAH patients. Nicardipine was administered by short-time continuous infusion (1 μg·kg-1·min-1 for 5 min and 2 μg·kg-1·min-1 for 5 min) followed by bolus injection (5 μg/kg). Hemodynamic responses were continuously measured using a right heart catheter. Acute responders were defined as patients who showed a decrease in mean pulmonary artery pressure of at least 10 mmHg to an absolute level below 40 mmHg with preserved or increased cardiac output. Two acute responders and sixty-three non-acute responders were identified. There was no hemodynamic instability requiring additional inotropic agents or death during the testing. Acute responders had good responses to long-term oral CCBs. The acute vasoreactivity testing with nicardipine might be safe and useful for identifying CCB responders in PAH patients.",
keywords = "Acute vasoreactivity testing, Calcium-channel blocker, Pulmonary arterial hypertension",
author = "Yukihiro Saito and Kazufumi Nakamura and Katsumasa Miyaji and Satoshi Akagi and Hiroki Mizoguchi and Aiko Ogawa and Soichiro Fuke and Hideki Fujio and Takahiko Kiyooka and Satoshi Nagase and Kunihisa Kohno and Hiroshi Morita and Kusano, {Kengo F.} and Hiromi Matsubara and Tohru Ohe and Hiroshi Itoh",
year = "2012",
doi = "10.1254/jphs.12114FP",
language = "English",
volume = "120",
pages = "206--212",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8648",
publisher = "The Japanese Pharmacological Society",
number = "3",

}

TY - JOUR

T1 - Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension

AU - Saito, Yukihiro

AU - Nakamura, Kazufumi

AU - Miyaji, Katsumasa

AU - Akagi, Satoshi

AU - Mizoguchi, Hiroki

AU - Ogawa, Aiko

AU - Fuke, Soichiro

AU - Fujio, Hideki

AU - Kiyooka, Takahiko

AU - Nagase, Satoshi

AU - Kohno, Kunihisa

AU - Morita, Hiroshi

AU - Kusano, Kengo F.

AU - Matsubara, Hiromi

AU - Ohe, Tohru

AU - Itoh, Hiroshi

PY - 2012

Y1 - 2012

N2 - Acute vasoreactivity testing for patients with pulmonary arterial hypertension (PAH) has been reported to be useful to identify patients with sustained beneficial response to oral calcium-channel blockers (CCBs), but there is a risk of exacerbation during the testing with oral CCBs. Therefore, we developed a testing method utilizing intravenous nicardipine, a short-acting CCB, and examined the safety and usefulness of acute vasoreactivity testing with nicardipine in PAH patients. Acute vasoreactivity testing with nicardipine was performed in 65 PAH patients. Nicardipine was administered by short-time continuous infusion (1 μg·kg-1·min-1 for 5 min and 2 μg·kg-1·min-1 for 5 min) followed by bolus injection (5 μg/kg). Hemodynamic responses were continuously measured using a right heart catheter. Acute responders were defined as patients who showed a decrease in mean pulmonary artery pressure of at least 10 mmHg to an absolute level below 40 mmHg with preserved or increased cardiac output. Two acute responders and sixty-three non-acute responders were identified. There was no hemodynamic instability requiring additional inotropic agents or death during the testing. Acute responders had good responses to long-term oral CCBs. The acute vasoreactivity testing with nicardipine might be safe and useful for identifying CCB responders in PAH patients.

AB - Acute vasoreactivity testing for patients with pulmonary arterial hypertension (PAH) has been reported to be useful to identify patients with sustained beneficial response to oral calcium-channel blockers (CCBs), but there is a risk of exacerbation during the testing with oral CCBs. Therefore, we developed a testing method utilizing intravenous nicardipine, a short-acting CCB, and examined the safety and usefulness of acute vasoreactivity testing with nicardipine in PAH patients. Acute vasoreactivity testing with nicardipine was performed in 65 PAH patients. Nicardipine was administered by short-time continuous infusion (1 μg·kg-1·min-1 for 5 min and 2 μg·kg-1·min-1 for 5 min) followed by bolus injection (5 μg/kg). Hemodynamic responses were continuously measured using a right heart catheter. Acute responders were defined as patients who showed a decrease in mean pulmonary artery pressure of at least 10 mmHg to an absolute level below 40 mmHg with preserved or increased cardiac output. Two acute responders and sixty-three non-acute responders were identified. There was no hemodynamic instability requiring additional inotropic agents or death during the testing. Acute responders had good responses to long-term oral CCBs. The acute vasoreactivity testing with nicardipine might be safe and useful for identifying CCB responders in PAH patients.

KW - Acute vasoreactivity testing

KW - Calcium-channel blocker

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=84869390636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869390636&partnerID=8YFLogxK

U2 - 10.1254/jphs.12114FP

DO - 10.1254/jphs.12114FP

M3 - Article

C2 - 23117888

AN - SCOPUS:84869390636

VL - 120

SP - 206

EP - 212

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8648

IS - 3

ER -